Active, not recruitingPhase 2NCT03854032
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Studying Lymphoid interstitial pneumonia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Thomas Jefferson University
- Principal Investigator
- Adam Luginbuhl, MDSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Intervention
- Nivolumab(biological)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (2)
- Ohio State University, Columbus, Ohio, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03854032 on ClinicalTrials.govOther trials for Lymphoid interstitial pneumonia
Additional recruiting or active studies for the same condition.